Treatment of Klebsiella pneumoniae ESBL Infections

Rationale for Ineffectiveness of Certain Antibiotics

• First-generation cephalosporins like cephalexin lack activity against ESBL-producing organisms, which are resistant to most beta-lactam antibiotics including all first, second, and third-generation cephalosporins 1, 3
• The Infectious Diseases Society of America recommends against using first-generation cephalosporins for treating ESBL infections due to their lack of effectiveness 1, 3

Recommended Treatment Options

• Carbapenems, such as ertapenem, imipenem/cilastatin, meropenem, or doripenem, are effective against ESBL-producing pathogens and are traditionally considered agents of choice for ESBL infections 1, 4
• The European Society of Clinical Microbiology and Infectious Diseases recommends ceftazidime/avibactam as a first-line treatment for infections caused by ESBL and KPC-producing Enterobacterales 2, 5
• Ceftazidime/avibactam shows higher clinical success rates compared to other regimens and has a lower risk of nephrotoxicity compared to colistin-based regimens 6
• Meropenem/vaborbactam is strongly recommended as a first-line treatment for KPC-producing Enterobacterales and is associated with higher clinical cure rates and decreased mortality compared to best available therapy 5, 6
• The American College of Clinical Pharmacy recommends considering carbapenem-sparing regimens, such as ceftolozane/tazobactam (with metronidazole), for less severe ESBL infections 3, 7

Treatment Algorithm

• Confirm ESBL production through cultures and antimicrobial susceptibility testing to guide therapy 8
• Assess infection severity and site, and use carbapenems or newer beta-lactam/beta-lactamase inhibitor combinations for severe infections or bacteremia 2, 5
• Consider local resistance patterns to guide empiric therapy choices, as recommended by the Centers for Disease Control and Prevention 1
• Implement carbapenem-sparing strategies when possible to reduce selection pressure for carbapenem-resistant organisms 9, 7

Important Considerations

• Rapid identification of the specific carbapenemase mechanism is crucial for optimizing therapy in carbapenem-resistant isolates, according to the World Health Organization 2
• Combination therapy may be considered for severe infections, though evidence for superiority over monotherapy with newer agents is limited, as noted by the Infectious Diseases Society of America 10